A fast-read primer on India's pharmaceuticals and biotechnology sector — the backdrop against which we benchmark every company's cost structure in this category.
The domestic market keeps growing at a steady clip, alongside consistently rising pharma exports.
2025 → 2031 forecast
FY25 → FY26
Global leadership in generics, robust biotech growth, and strong policy support define the sector.
A sample of the industry-wide and policy moves shaping the sector through early 2026.
Listed Indian Pharmaceuticals & Biotechnology companies in tDoBe's cost-benchmarking coverage.
The market facts above are public background. What follows is tDoBe's own work: every "Other Expenses" line from these companies' own financial records, read by hand and sorted into one clear set of categories — not a keyword search, not each company's own way of reporting it.
Each mark is one company's total Other Expenses as % of net revenue. No company is named here.
Ranked from biggest to smallest.
Miscellaneous/Others leads at 3.6% of revenue, with Advertising & Sales Promotion (2.8%) and Legal & Professional Fees (2.2%) close behind — and R&D/Product Development shows up here at a scale not seen in most other sectors we've benchmarked, a genuine feature of pharmaceutical manufacturing.
Branded-formulation manufacturers in this peer set carry meaningfully more advertising spend than the API and contract-development specialists — a real business-model split — though it keeps this sector's spread comparatively tight at 2.2x, one of the narrowest we've measured.
All ten companies collected for this sector are genuine large-to-mid-cap operating pharmaceutical or biotech manufacturers and are used in every Other Expenses ratio, with no exclusions.
This is the free, sector-wide view. It tells you where Pharmaceuticals & Biotechnology stands as a whole — not where your own company stands against it, category by category, in rupees.
A below-average number is a reason to call too — the benchmark keeps improving as we go.